Memphasys Reproductive Biotechnology @memphasys - Tumblr Blog

We’re excited to share that our Felix™ System is nearing the completion of its clinical trial in Australia, with 95% of patient recruitment already completed. If current recruitment rates are maintained, the study is expected to conclude by the end of this calendar year. This will provide us with essential data to support our regulatory submissions and market expansion efforts. As demand for innovative fertility solutions continues to rise, Memphasys is positioning itself at the forefront of the global assisted reproductive technology (ART) market.

Read more : https://www.memphasys.com/memphasys-targets-global-fertility-market-as-clinical-trial-nears-completion/

At Memphasys Limited, we are proud to announce a major breakthrough in biotechnology with the filing of a patent for our cutting-edge antioxidant assay system, RoXsta™. This pioneering innovation is set to transform the way oxidative stress is measured, offering groundbreaking advancements for industries ranging from healthcare to food quality control.

Read more : https://www.memphasys.com/memphasys-innovative-roxsta-system-redefining-oxidative-stress-measurement/

This past financial year has been full of significant milestones and continued growth for us at Memphasys. From launching our Felix™ System in new markets to expanding our partnerships globally, we’ve been laser-focused on our mission to advance reproductive technology for both humans and animals.

Read more : https://www.memphasys.com/looking-back-a-year-of-growth-and-progress-at-memphasys/

The field of assisted reproductive technology (ART) is experiencing rapid advancements, benefiting both human and animal fertility. In this evolving landscape, we at Memphasys are driving innovation with our specialised products, such as the Felix™ System for sperm selection in ART and our Memphasys Animal Breeding Solutions (MABS) for semen transport and storage in animal reproduction. As technologies such as cryopreservation continue to progress, we remain at the forefront, offering solutions designed to improve fertility outcomes and meet the demands of the reproductive health market.

Read more : https://www.memphasys.com/advancements-in-fertility-technology-memphasys-cutting-edge-solutions/

Memphasys has brought on board Mike Cameron, a leading animal fertility consultant to accelerate their animal fertility program. This collaboration aims to expand Memphasys’ current work on their AI Port product and enhance their animal fertility portfolio under MABS (Memphasys’ Animal Breeding Solutions).

Mike will coordinate and provide insights into the animal breeding industry, focusing on connecting innovative concepts with practical commercial applications. His primary goal is to develop oxidative stress thresholds in cattle.

Read more : https://www.memphasys.com/memphasys-animal-fertility-mike-cameron/

We’re excited to announce that we’ve embarked on a three-year equine fertility study aimed at establishing our Felix™ device as a leading technology for equine sperm selection. This study is set to open up significant commercial opportunities within the next 12 months.

In collaboration with the University of Newcastle and EquiBreedUK Ltd, and with the support of top Thoroughbred stud farms, we’re taking major steps toward transforming the way equine breeders manage fertility. Our goal is to offer a cutting-edge solution for equine sperm selection that can be quickly adopted across the industry.

Read more : https://www.memphasys.com/equine-fertility-breakthrough-felix-device-positioned-for-global-market-launch/

Memphasys Scientific Director, Laureate Professor John Aitken, is a truly global leader in the field of reproductive biology and has been pivotal in the development of the FelixTM sperm separation device, which is currently at various stages along the commercialisation journey and helping people build families around the world. And just as important as his work with fertility among people, is his work in animal fertility, which it could be said is equally valuable to the future of our society.

Read more : https://www.memphasys.com/memphasys-qa-on-a-mission-to-fine-tune-animal-fertility/

Male infertility has emerged as a significant health issue in India, accounting for nearly 40-50% of all infertility cases. This problem is often overshadowed by the more commonly discussed issue of female infertility, leaving many men to suffer in silence. However, as the prevalence of male infertility continues to rise, it’s becoming clear that this is a problem that demands attention, awareness, and innovative solutions.

Read more : https://www.memphasys.com/male-infertility-in-india-new-solutions-on-the-horizon/

During the last financial year, MEM undertook a significant change of management, leading to a more structured and refined business plan. This transition, along with a shift to hybrid working, reduced the need for a large office environment. The old offices were ideal previously, due to their extensive laboratory and manufacturing capabilities. However, with current product development occurring at the University of Newcastle, and manufacturing conducted by various third parties; the old premises were no longer required. This resulted in the business relocation to an adjacent building, enabling asignificant reduction in rent and other costs.

Read more : https://www.memphasys.com/memphasys-embracing-a-contemporary-work-environment-and-keeping-costs-in-check-with-a-new-office-move/

We are excited to announce significant financial developments that promise to propel our innovative projects forward. These new funds are set to support the expansion of the Felix™ System’s commercial activities in Japan and the Australian clinical trials, among other key initiatives.

Read more : https://www.memphasys.com/over-1m-in-funding-secured-to-accelerate-innovations-in-reproductive-biotechnology/

We are continuing to make significant strides in the field of assisted reproductive technology (ART). With the recent progress in sales, product development, and clinical trials, we are poised to transform IVF procedures and reproductive health both in humans and animals.

Read more : https://www.memphasys.com/pioneering-advances-in-assisted-reproductive-technology/

As fertility rates fall in advanced industrialised nations and our populations become smaller and older, it is crucial that we recognise the pressure that young people (men and women) will be under to achieve the levels of productivity needed to buoy up their national economies. Under these all-hands-to-the-pump circumstances, any procreative drive will be pushed into the background as our youngest and finest make their way in an increasingly competitive world. Having babies will be the last thing on their minds and by the time this desire struggles to the surface and breathes oxygen, it will be too late.

Read more : https://www.memphasys.com/social-change-rethinking-parenthood-work-and-marriage-in-a-changing-world/

We continue to maintain our ISO 13485 certification, a testament to our commitment to the highest standards of quality management in the medical device industry since May 2022.

ISO 13485 is an internationally recognized standard designed specifically for the medical device industry. It ensures consistent design, development, production, and delivery of medical devices that meet stringent regulatory requirements. This certification underscores our dedication to safety and quality, essential in every step of a product’s life cycle, including service and delivery.

Read more : https://www.memphasys.com/memphasys-maintains-iso-13485-certification-a-new-milestone-in-quality-and-innovation/

An example of environmental/lifestyle impacts on male reproduction that is not strongly correlated with sperm number per se but is a major determinant of sperm function – is oxidative stress. Spermatozoa are very vulnerable to oxidative stress largely because their intrinsic lack of cytoplasm places constraints on the antioxidant enzymes and free radical scavengers available to protect these cells.

Read more : https://www.memphasys.com/countering-oxidative-stress-the-crucial-impact-on-male-reproduction-and-infertility-solutions/

Transforming semen separation to improve speed, accuracy, ease of use and to reduce operator error.

The progress of ART (Assisted Reproductive Technology) procedures has come into sharp focus as global infertility is on the rise. There is also a broadly held belief that there’s been a lack of innovation in andrology for the past 40 years. The male side of fertility has been the ‘forgotten half’ and has lagged for years compared to the female side. These issues are discussed and presented by Professor John Aitken in his book – The Infertility Trap (Cambridge University Press).

Read more : https://www.memphasys.com/the-aims-of-the-felix-device/

Extract from The Infertility Trap by Laureate Professor John Aitken, Scientific Director at Memphasy.

Regulators should be aware of the potential threat posed by toxicants in the environment of human fertility. The profile of reproductive toxicology needs to be raised such that every new compound released into our ecosystems has been rigorously tested for reproductive impacts.

Read more : https://www.memphasys.com/raising-awareness-the-vital-role-of-reproductive-toxicology-in-protecting-human-fertility/

Extract from the Infertility Trap:

As the global decline in fertility rates gradually overwhelms population momentum, we shall see a progressive fall in the number of human beings inhabiting our planet. For many of us, this is a cause of celebration; we want the world population to shrink so that our environment has an opportunity to catch its breath and recover from the ravages of unprecedented population growth.

Read more : https://www.memphasys.com/navigating-the-path-to-population-equilibrium-challenges-and-solutions-for-a-sustainable-future/

Trending Blogs

Recently Viewed Blogs

Memphasys Reproductive Biotechnology